For the Inventor, By the Inventor

Enter assignee name

Barcelona, Spain

Ferrer Internacional, S.a.

USPTO Granted Patents = 48

% Expired Patents = 35.4

CIPO Patents = 7

EPO Patents = 24

Trademarks = 5

Forward Citations = 57

Loading Chart...

Loading Chart...

67 inventors (with patents filed for the assignee):

Rafael Foguet (26 out of 29 patents)

Aurelio Sacristan (17 out of 19 patents)

Jose A Ortiz (17 out of 19 patents)

4. Antonio Guglietta (14 out of 21 patents)

5. Albert Palomer (12 out of 15 patents)

6. Josep M Castello (11 out of 11 patents)

7. Manuel M Raga (10 out of 15 patents)

8. Luis Anglada (8 out of 11 patents)

9. Jorge Ramentol (6 out of 6 patents)

10. Ernesto Forne (6 out of 6 patents)

11. Inés Petschen (5 out of 5 patents)

12. Lluis Anglada (5 out of 5 patents)

13. Jordi Bolos (4 out of 4 patents)

14. Santiago Gubert (4 out of 5 patents)

15. Juan Sallares (3 out of 5 patents)

Core Competencies:

Pharmaceutical Compositions

Cardiovascular Treatments

Insomnia Therapies

Nutraceuticals

Pyrimidine Derivatives

Topical Compositions

Imidazole Compounds

Choline Derivatives

Oxazolidinone Compounds

Sulfonamides

Piperidine Derivatives

48 patents: Sort by Forward Citations

1. 12533371 - Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof (2026-01-27),

2. 10617699 - Oral formulation for the treatment of cardiovascular diseases (2020-04-14),

3. 10072000 - Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines (2018-09-11),

4. 10022363 - Pharmaceutical topical compositions (2018-07-17),

5. 9399014 - Pharmaceutical topical compositions (2016-07-26),

6. 8993562 - Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions (2015-03-31),

7. 8753680 - Capsule for the prevention of cardiovascular diseases (2014-06-17),

8. 8545816 - Benzoic acid ester compounds, compositions, uses and methods related thereto (2013-10-01),

9. 8530482 - Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates (2013-09-10),

10. 8507684 - 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts (2013-08-13),

11. 8227501 - [object Object] (2012-07-24),

12. 8158632 - [object Object] (2012-04-17),

13. 8153789 - Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions (2012-04-10),

14. 8106202 - Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor (2012-01-31),

15. 8039476 - Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide (2011-10-18),

Ferrer Internacional, S.A., headquartered in Barcelona, Spain, is a prominent pharmaceutical company specializing in the development and manufacturing of innovative therapies. The organization focuses on addressing cardiovascular diseases and mental health conditions through advanced pharmaceutical compositions, including halogenated pyrazolo compounds, imidazo compounds, and oxazolidinone derivatives. Ferrer is committed to enhancing patient outcomes by leveraging its expertise in various therapeutic areas, particularly in the fields of antidepressants and neurological health.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Ferrer Internacional, S.a.

48 Patents

#10 in Barcelona

#31 in Spain

#14,536 in the World

Barcelona, Spain

Ferrer Internacional, S.a.

Forward Citations = 57

67 inventors:

Rafael Foguet (26 out of 29 patents)

Aurelio Sacristan (17 out of 19 patents)

Jose A Ortiz (17 out of 19 patents)

4. Antonio Guglietta (14 out of 21 patents)

5. Albert Palomer (12 out of 15 patents)

Please report any incorrect information to [email protected]

Loading…